Esketamine hydrochloride

Phase 3Small molecule

TThe Second Hospital of Anhui Medical University

Esketamine hydrochloride is one of 220 small molecule programs targeting Schizophrenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

219

Competitors

Pipeline

Status by Indication[3][1]

Indication

SchizophreniaActive, not recruiting

Laparoscopic Sleeve GastrectomyUnknown status

Cardiac ArrestRecruiting

Rett SyndromeActive, not recruiting

Major Depressive DisorderRecruiting

EndometriosisRecruiting

EsketamineRecruiting

TonsillectomyRecruiting

Efficacy and SafetyNot yet recruiting

Treatment Resistant DepressionRecruiting

SchizophreniaPreclinical

Active, not recruiting

Laparoscopic Sleeve GastrectomyPreclinical

Unknown status

Cardiac ArrestPhase 2

Recruiting

Rett SyndromePhase 1

Active, not recruiting

Major Depressive DisorderPhase 3

Recruiting

EndometriosisPhase 3

Recruiting

EsketaminePhase 3

Recruiting

TonsillectomyPhase 3

Recruiting

Efficacy and SafetyPhase 3

Not yet recruiting

Treatment Resistant DepressionPhase 3

Recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

BESREMI

PPharmaEssentia

Phase 3

2 2

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 3

Avalglucosidase Alfa

Sanofi

Phase 3

1 4

Esketamine hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 5

Tpoxx

SSIGA Technologies

Phase 3

1 6

VAY736

Novartis

Phase 3

2 7

Hemay005

GGanzhou Hemay Pharmaceutical Co., Ltd

Phase 3

2 8

CBL-514

CCaliway Biopharmaceuticals Co., Ltd.

Phase 3

3 9

IN-B00009

HHK inno.N Corporation

Phase 3

1 10

ZM-H1505R

SShanghai Zhimeng Biopharma, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Esketamine

NCT04843982

Post-ApprovalRecruiting

Treatment Resistant Depression

NCT07369102

Post-ApprovalNot yet recruiting

Efficacy and Safety

NCT07063108

Q3 2027

Phase 2Recruiting

Cardiac Arrest

NCT06744361

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05973851

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973851·418 enrolled

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

Esketamine2 trials

Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00847418

Immunoinflammatory Regulation of Esketamine in Septic Patients

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT04843982·100 enrolled

Complication1 trial

To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications

Recruiting·ZZhang XIao Mei·Phase 4·NCT06467513·102 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of S-ketamine in Elderly Patients Undergoing Non-cardiac Surgery: a RCT（ESSENCE）

Not yet recruiting·—·Phase 4·NCT07063108·276 enrolled

Cardiac Arrest1 trial

Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest

Recruiting·CChristian Hassager·Phase 2·NCT06744361·282 enrolled

6 more indications

Treatment Resistant Depression1 trial

Esketamine With or Without Integration Therapy for Treatment-Resistant Depression

Recruiting·UUniversity of Puerto Rico·Phase 4·NCT07369102·20 enrolled

Rett syndrome1 trial

Esketamine for the Treatment of Rett Syndrome

Active, not recruiting·—·Phase 1·NCT06199700·3 enrolled

Endometriosis1 trial

Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study

Recruiting·RReinier de Graaf Groep·Phase 3·NCT06161805·56 enrolled

Laparoscopic Sleeve Gastrectomy1 trial

Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy

Unknown status·TThe Second Hospital of Anhui Medical University·N/A·NCT06199011·400 enrolled

Schizophrenia1 trial

Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)

Completed·MMedical University of Vienna·N/A·NCT01394757·52 enrolled

Tonsillectomy1 trial

Effects of Esketamine on Postoperative Behavioral Changes in Children Undergoing Tonsillectomy and/or Adenoidectomy

Recruiting·FFujian Provincial Hospital·Phase 4·NCT06579937·172 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Esketamine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Esketamine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Esketamine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Hospital of Anhui Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Second Hospital of Anhui Medical University

Esketamine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q2 2028

Trials by Indication[1]

Major Depressive Disorder2 trials

Esketamine2 trials

Complication1 trial

Efficacy and Safety1 trial

Cardiac Arrest1 trial

Treatment Resistant Depression1 trial

Rett syndrome1 trial

Endometriosis1 trial

Laparoscopic Sleeve Gastrectomy1 trial

Schizophrenia1 trial

Tonsillectomy1 trial

References

Drug Info

Quick Facts

Related News